Events

ESMO 2021: Maintenance Olaparib in Ovarian Cancer

By ONA Editor September 23, 2021 No Comments

Highlights on maintenance olaparib in ovarian cancer previously treated with PARPi

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

About Author

Related Posts

AACR 2026: Phase 1 study explores toxicity reduction in combination of trastuzumab deruxtecan and olaparib in advanced HER2-expressing malignancies

New study finds common blood pressure drug boosts cancer treatment

“Electronic nose” may help identify ovarian cancer signatures from blood samples

Leave A Reply Cancel Reply